Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05655156

OrthoPureXT Multiligament PMCF Study

To monitor residual risks in the post-market phase and to ensure continued clinical evaluation of the device safety and performance to ensure that no new or unexpected risks arise when used during multi-ligament knee reconstructions.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Royal Stoke University Hospital

Stoke-on-Trent, ST4 6QG, United Kingdom

Location status: Recruiting

About this study

OrthoPureXT is an acellular, sterile, single use, xenograft (porcine) tissue scaffold that is manufactured using a proprietary decellularisation technology that renders the tissue substantially free from cells, leaving the porcine tissue biocompatible, and safe for implantation into the knee.

28 patients in total to be evenly distributed across potential ligament reconstruction treatment options (n=7 per sub-group) and resulting in a statistically relevant number per sub-group considering potential loss to follow up.

Sub-groups of n=7 incurring ligament reconstruction using OrthoPure XT in the following anatomical locations:

  • Posterior cruciate ligament (PCL)
  • Anterior cruciate ligament (ACL)
  • Posteromedial corner including the medial collateral ligament (MCL)
  • Posterolateral corner including the lateral collateral ligament (LCL)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients aged 18 years old or above.
  • Adults suffering with multiple knee ligament injuries.
  • Ability to communicate meaningfully with investigative staff, competence to give written informed consent; and willingness and ability to comply with entire study procedures including rehabilitation protocol.

Exclusion criteria

  • Those unable to give consent.
  • Those considered as conflicting variables by the investigator. This may include, but is not limited to:
  • Open trauma
  • Neurovascular emergencies
  • Compartment syndrome
  • Life threatening injury
  • Those considered as physical barriers by the investigator, preventing physical or ethical collection of study data. This may include, but is not limited to:
  • Associated fractures that require external fixators
  • Local severe concomitant injuries
  • Injuries to other parts of the body associated with a high level of daily activity/intervention for the patient
  • Those considered as a poor candidate for surgery by the investigator.
  • If female and of child-bearing potential must not have a positive pregnancy test at Visit

1 nor have a stated intention to become pregnant in the next 12 months.

  • Those patients contraindicated for in the IFU, i.e.:
  • Showing signs of infection within 24 hours prior to surgery
  • Patients with known allergy, hypersensitivity, or religious objection to, implanted porcine material
  • Patients unable or unwilling to follow the post-operative care and rehabilitation programme

Treatment and study plan

OrthoPure XT

Device

Indication: reconstruction of knee ligaments to restore knee function and stability

The following device sizes are available for use in this indication:

  • Size 5
  • Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)
  • Size 6
  • Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)
  • Size 8
  • Primary ACL reconstruction where autograft tissue is not suitable
  • Revision ACL reconstruction
  • Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)
  • Size 10
  • Multi-ligament reconstruction (recommended for posterior cruciate ligament (PCL) reconstruction)

Primary outcomes

  1. A change from Baseline in IKDC

    Time frame: Baseline (30 days prior to surgery); 1, 3, 6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up)

    Assessment of knee stability via evaluation of IKDC score.

Secondary outcomes

  1. A change from Baseline in Lysholm

    Time frame: Baseline (30 days prior to surgery); 1, 3 ,6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up)

    Assessment of knee stability via evaluation of Lysholm score.

  2. A change from Baseline in KOOS

    Time frame: Baseline (30 days prior to surgery); 1, 3, 6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up)

    Assessment of knee stability via evaluation of KOOS.

  3. A change from Baseline in Assessment of Laxity via Physical Examination

    Time frame: Baseline (30 days prior to surgery); 1, 3, 6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up)

    Physical assessment of passive movement focusing on the reconstructed ligament.

Study contacts

Contact information is provided by the study sponsor or research team.

Anna Kaniewska

CONTACT

[email protected]

+44 (0)3304303052

Sponsors and collaborators

Lead sponsor

Tissue Regenix Ltd

Industry

Registry information

Official study title

Post Market Clinical Follow-Up of OrthoPureXT for the Treatment of Multiligament Injured Knee: a Case Series

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 19, 2022
Registry last updated
Apr 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.